Gabelli Has Buy on Hospira

Gabelli & Co. is out with a research report on Hospira Inc (NYSE: HSP) and it has a Buy rating on shares.

In a note to clients, Gabelli & Co. writes, "The stock has lost 40% of its value, falling over $20 per share, over the past four months due to continued quality control problems to both sides of the business that first surfaced in 2010. Hospira is the global leader in the $12 bn generic injectable market."

Shares of HSP closed at $30.98 yesterday.